VEL-101
Product
Veloxis Pharmaceuticals, Inc.
Total Payments
$784,213
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $784,213 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $784,213 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 | Veloxis Pharmaceuticals, Inc. | $784,213 | 0 |
Top Doctors Receiving Payments for VEL-101
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Covington, KY | $784,213 | 2 |
Ad
Manufacturing Companies
- Veloxis Pharmaceuticals, Inc. $784,213
Product Information
- Type Product
- Total Payments $784,213
- Total Doctors 0
- Transactions 2
About VEL-101
VEL-101 is a product associated with $784,213 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Veloxis Pharmaceuticals, Inc..
Payment data is available from 2022 to 2022. In 2022, $784,213 was paid across 2 transactions to 0 doctors.
The most common payment nature for VEL-101 is "Unspecified" ($784,213, 100.0% of total).
VEL-101 is associated with 1 research study, including "A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101" ($784,213).